{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:06:51Z","timestamp":1790309211788,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,21]]},"DOI":"10.7759\/cureus.69837","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T09:39:58Z","timestamp":1726911598000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Empagliflozin on the Outcomes of \u03b2-Thalassemia Major in Patients With Type 2 Diabetes Mellitus: The THALEMPA Observational Study"],"prefix":"10.7759","author":[{"given":"Anas","family":"Ibraheem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem F","family":"Al Tameemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"21","author":"Galanello R","year":"2010","unstructured":"Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010, 21:11. 10.1186\/1750-1172-5-11","journal-title":"Orphanet J Rare Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.173","article-title":"\u03b2-Thalassemia","volume":"19","author":"Origa R","year":"2017","unstructured":"Origa R. \u03b2-Thalassemia. Genet Med. 2017, 19:609-19. 10.1038\/gim.2016.173","journal-title":"Genet Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13512","article-title":"Changing patterns in the epidemiology of \u03b2-thalassemia","volume":"105","author":"Kattamis A","year":"2020","unstructured":"Kattamis A, Forni GL, Aydinok Y, et al.. Changing patterns in the epidemiology of \u03b2-thalassemia. Eur J Haematol. 2020, 105:692-703. 10.1111\/ejh.13512","journal-title":"Eur J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101138","article-title":"Management of transfusion-dependent \u03b2-thalassemia (TDT): expert insights and practical overview from the Middle East","volume":"63","author":"El-Beshlawy A","year":"2024","unstructured":"El-Beshlawy A, Dewedar H, Hindawi S, et al.. Management of transfusion-dependent \u03b2-thalassemia (TDT): expert insights and practical overview from the Middle East. Blood Rev. 2024, 63:101138. 10.1016\/j.blre.2023.101138","journal-title":"Blood Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27166","article-title":"Defining curative endpoints for transfusion-dependent \u03b2-thalassemia in the era of gene therapy and gene editing","author":"Corbacioglu S","year":"2023","unstructured":"Corbacioglu S, Frangoul H, Locatelli F, et al.. Defining curative endpoints for transfusion-dependent \u03b2-thalassemia in the era of gene therapy and gene editing. Am J Hematol. 2023, 10.1002\/ajh.27166","journal-title":"Am J Hematol"},{"key":"ref6","article-title":"Thalassemia","author":"Bajwa H","year":"2023","unstructured":"Bajwa H, Basit H. Thalassemia. StatPearls, Treasure Island, FL; 2023."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.22631\/ijbmph.2018.56102","article-title":"Thalassemia an update: molecular basis, clinical features and treatment","volume":"1","author":"Tari K","year":"2018","unstructured":"Tari K, Ardalan PV, Abbaszadehdibavar M, et al.. Thalassemia an update: molecular basis, clinical features and treatment. Int J BioMed Public Health. 2018, 1:48-58. 10.22631\/ijbmph.2018.56102","journal-title":"Int J BioMed Public Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher AT","year":"2018","unstructured":"Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018, 391:155-67. 10.1016\/S0140-6736(17)31822-6","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/joah.joah_1_18","article-title":"Knowledge and response of the community to premarital screening program (Sickle Cell Anemia\\Thalassemia); AlMadinah, Saudi Arabia","volume":"9","author":"AlQahtani RS","year":"2018","unstructured":"AlQahtani RS, Bedaiwi AA, Alburkani AM, et al.. Knowledge and response of the community to premarital screening program (Sickle Cell Anemia\\Thalassemia); AlMadinah, Saudi Arabia. J Appl Hematol. 2018, 9:59. 10.4103\/joah.joah_1_18","journal-title":"J Appl Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2017.039","article-title":"Analysis of factors that influence hematopoietic recovery in autologous transplanted patients with hematopoietic stem cells from peripheral blood","volume":"5","author":"Grubovic RM","year":"2017","unstructured":"Grubovic RM, Georgievski B, Cevreska L, et al.. Analysis of factors that influence hematopoietic recovery in autologous transplanted patients with hematopoietic stem cells from peripheral blood. Open Access Maced J Med Sci. 2017, 5:324-31. 10.3889\/oamjms.2017.039","journal-title":"Open Access Maced J Med Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1788","article-title":"Current status of beta-thalassemia and its treatment strategies","volume":"9","author":"Ali S","year":"2021","unstructured":"Ali S, Mumtaz S, Shakir HA, et al.. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021, 9:1788. 10.1002\/mgg3.1788","journal-title":"Mol Genet Genomic Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031805","article-title":"Comparison of effectiveness among different sodium-glucose Cotransoporter-2 inhibitors according to underlying conditions: a network meta-analysis of randomized controlled trials","volume":"13","author":"Kani R","year":"2024","unstructured":"Kani R, Watanabe A, Miyamoto Y, et al.. Comparison of effectiveness among different sodium-glucose Cotransoporter-2 inhibitors according to underlying conditions: a network meta-analysis of randomized controlled trials. J Am Heart Assoc. 2024, 13:031805. 10.1161\/JAHA.123.031805","journal-title":"J Am Heart Assoc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu B","year":"2022","unstructured":"Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol. 2022, 21:83. 10.1186\/s12933-022-01512-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi SE","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, et al.. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial.  Diab Care. 2018, 41:356-63. 10.2337\/dc17-1096","journal-title":"Diab Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.08.004","article-title":"Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes","volume":"8","author":"Li J","year":"2020","unstructured":"Li J, Woodward M, Perkovic V, et al.. Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. JACC Heart Fail. 2020, 8:57-66. 10.1016\/j.jchf.2019.08.004","journal-title":"JACC Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.04.051","article-title":"Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes","volume":"98","author":"Li J","year":"2020","unstructured":"Li J, Neal B, Perkovic V, et al.. Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. Kidney Int. 2020, 98:769-77. 10.1016\/j.kint.2020.04.051","journal-title":"Kidney Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1663","article-title":"Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial","volume":"22","author":"B\u00f6hm M","year":"2020","unstructured":"B\u00f6hm M, Slawik J, Brueckmann M, et al.. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur J Heart Fail. 2020, 22:126-35. 10.1002\/ejhf.1663","journal-title":"Eur J Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of Empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer CD","year":"2020","unstructured":"Mazer CD, Hare GMT, Connelly PW, et al.. Effect of Empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2020, 141:704-07. 10.1161\/CIRCULATIONAHA.119.044235","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-1022","article-title":"The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wang X","year":"2021","unstructured":"Wang X, Fu R, Liu H, Ma Y, Qiu X, Dong Z. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. 2021, 10:6467-81. 10.21037\/apm-21-1022","journal-title":"Ann Palliat Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad171","article-title":"Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology","volume":"38","author":"Gangat N","year":"2023","unstructured":"Gangat N, Tefferi A. Sodium-glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology. Nephrol Dial Transplant. 2023, 38:2670-2. 10.1093\/ndt\/gfad171","journal-title":"Nephrol Dial Transplant"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17115","article-title":"Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: a meta-analysis","volume":"26","author":"Tian Q","year":"2022","unstructured":"Tian Q, Guo K, Deng J, Zhong Y, Yang L. Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: a meta-analysis. J Cell Mol Med. 2022, 26:540-7. 10.1111\/jcmm.17115","journal-title":"J Cell Mol Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27048","article-title":"Sodium-glucose co-transporter-2 inhibitor treatment in essential thrombocythemia: Impact on hemoglobin\/hematocrit levels and outcomes among 11 consecutive patients","volume":"98","author":"Gangat N","year":"2023","unstructured":"Gangat N, Reichard K, Tefferi A. Sodium-glucose co-transporter-2 inhibitor treatment in essential thrombocythemia: Impact on hemoglobin\/hematocrit levels and outcomes among 11 consecutive patients. Am J Hematol. 2023, 98:E298-300. 10.1002\/ajh.27048","journal-title":"Am J Hematol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13336","article-title":"Relationship between SGLT2 inhibitors and hemoglobin levels: a retrospective observational study","volume":"37","author":"Yoshida Y","year":"2023","unstructured":"Yoshida Y, Takahashi K, Hashimoto R, Oya T, Sato J. Relationship between SGLT2 inhibitors and hemoglobin levels: a retrospective observational study. In Vivo. 2023, 37:2327-33. 10.21873\/invivo.13336","journal-title":"In Vivo"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial","volume":"25","author":"Fuchs Andersen C","year":"2023","unstructured":"Fuchs Andersen C, Omar M, Glenth\u00f8j A, et al.. Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. Eur J Heart Fail. 2023, 25:226-34. 10.1002\/ejhf.2735","journal-title":"Eur J Heart Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-023-02174-0","article-title":"Masked anemia and hematocrit elevation under sodium glucose transporter inhibitors: findings from a large real-world study","volume":"61","author":"Schwarz Y","year":"2024","unstructured":"Schwarz Y, Klein P, Lev-Shalem L. Masked anemia and hematocrit elevation under sodium glucose transporter inhibitors: findings from a large real-world study. Acta Diabetol. 2024, 61:99-105. 10.1007\/s00592-023-02174-0","journal-title":"Acta Diabetol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03630-0","article-title":"Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients","volume":"98","author":"Chaloemwong J","year":"2019","unstructured":"Chaloemwong J, Tantiworawit A, Rattanathammethee T, et al.. Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients. Ann Hematol. 2019, 98:1101-10. 10.1007\/s00277-019-03630-0","journal-title":"Ann Hematol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino Y","year":"2014","unstructured":"Chino Y, Samukawa Y, Sakai S, et al.. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014, 35:391-404. 10.1002\/bdd.1909","journal-title":"Biopharm Drug Dispos"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051083","article-title":"SGLT2 inhibitors as a therapeutic option for diabetic nephropathy","author":"Kawanami D","year":"2017","unstructured":"Kawanami D, Matoba K, Takeda Y, et al.. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 2017, 1083-2017. 10.3390\/ijms18051083","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk DLS","year":"2022","unstructured":"Suijk DLS, van Baar MJB, van Bommel EJM, et al.. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function. Clin J Am Soc Nephrol. 2022, 17:663-71. 10.2215\/CJN.11480821","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21130","article-title":"A scoring system for the classification of beta-thalassemia\/Hb E disease severity","volume":"83","author":"Sripichai O","year":"2008","unstructured":"Sripichai O, Makarasara W, Munkongdee T, et al.. A scoring system for the classification of beta-thalassemia\/Hb E disease severity. Am J Hematol. 2008, 83:482-4. 10.1002\/ajh.21130","journal-title":"Am J Hematol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124675","article-title":"Development of a severity score system for thalassemia syndromes","volume":"134","author":"Vitrano A","year":"2019","unstructured":"Vitrano A, Meloni A, Pollina WA, et al.. Development of a severity score system for thalassemia syndromes. Blood. 2019, 134:2225. 10.1182\/blood-2019-124675","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36735","article-title":"Effects of Ramadan intermittent fasting on the severity of \u03b2-thalassemia major patients","volume":"15","author":"Ibraheem A","year":"2023","unstructured":"Ibraheem A. Effects of Ramadan intermittent fasting on the severity of \u03b2-thalassemia major patients. Cureus. 2023, 15:36735-10. 10.7759\/cureus.36735","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300049","article-title":"Dapagliflozin and anemia in patients with chronic kidney disease","volume":"2","author":"Koshino A","year":"2023","unstructured":"Koshino A, Schechter M, Chertow GM, et al.. Dapagliflozin and anemia in patients with chronic kidney disease. NEJM Evid. 2023, 2:2300049. 10.1056\/EVIDoa2300049","journal-title":"NEJM Evid"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065714","article-title":"Effects of semaglutide and empagliflozin on inflammatory markers in patients with type 2 diabetes","volume":"24","author":"Reppo I","year":"2023","unstructured":"Reppo I, Jakobson M, Volke V. Effects of semaglutide and empagliflozin on inflammatory markers in patients with type 2 diabetes. Int J Mol Sci. 2023, 24:5714. 10.3390\/ijms24065714","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2731","article-title":"How can sodium-glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure","volume":"24","author":"Packer M","year":"2022","unstructured":"Packer M. How can sodium-glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure. Eur J Heart Fail. 2022, 24:2287-96. 10.1002\/ejhf.2731","journal-title":"Eur J Heart Fail"},{"key":"ref36","article-title":"Alpha and beta thalassemia","volume":"80","author":"Muncie HL Jr","year":"2009","unstructured":"Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam Physician. 2009, 80:339-44.","journal-title":"Am Fam Physician"},{"key":"ref37","article-title":"Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)","author":"Cappellini MD","year":"2014","unstructured":"Cappellini MD, Cohen A, Porter J, et al.. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). Thalassaemia International Federation, Nicosia, NY; 2014."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2016.09.003","article-title":"Guidelines on Beta-thalassemia major - regular blood transfusion therapy: Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines Associa\u00e7\u00e3o M\u00e9dica Brasileira - 2016","volume":"38","author":"Langhi D Jr","year":"2016","unstructured":"Langhi D Jr, Ubiali EM, Marques JF Jr, et al.. Guidelines on Beta-thalassemia major - regular blood transfusion therapy: Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines Associa\u00e7\u00e3o M\u00e9dica Brasileira - 2016. Rev Bras Hematol Hemoter. 2016, 38:341-5. 10.1016\/j.bjhh.2016.09.003","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9944880","article-title":"Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways","author":"Lee N","year":"2021","unstructured":"Lee N, Heo YJ, Choi SE, et al.. Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways. J Immunol Res. 2021, 9944880. 10.1155\/2021\/9944880","journal-title":"J Immunol Res"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus","volume":"308","author":"Lytvyn Y","year":"2015","unstructured":"Lytvyn Y, \u0160krti\u0107 M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol. 2015, 308:F77-83. 10.1152\/ajprenal.00555.2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01182-y","article-title":"Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"15","author":"You Y","year":"2023","unstructured":"You Y, Zhao Y, Chen M, Pan Y, Luo Z. Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2023, 15:202. 10.1186\/s13098-023-01182-y","journal-title":"Diabetol Metab Syndr"},{"key":"ref42","article-title":"Renal complications of beta-thalassemia major in children","volume":"4","author":"Bakr A","year":"2014","unstructured":"Bakr A, Al-Tonbary Y, Osman G, et al.. Renal complications of beta-thalassemia major in children. Am J Blood Res. 2014, 4:1-6.","journal-title":"Am J Blood Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials","volume":"19","author":"Li D","year":"2017","unstructured":"Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017, 19:348-55. 10.1111\/dom.12825","journal-title":"Diabetes Obes Metab"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay MS","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al.. Effect of Empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018, 41:1801-8. 10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.836455","article-title":"Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"13","author":"Zhang Y","year":"2022","unstructured":"Zhang Y, Liu X, Zhang H, Wang X. Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022, 13:836455. 10.3389\/fendo.2022.836455","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.34172\/jcvtr.2021.18","article-title":"Evaluation of iron overload by cardiac and liver T2* in \u03b2-thalassemia: correlation with serum ferritin, heart function and liver enzymes","volume":"13","author":"Khadivi Heris H","year":"2021","unstructured":"Khadivi Heris H, Nejati B, Rezazadeh K, Sate H, Dolatkhah R, Ghoreishi Z, Esfahani A. Evaluation of iron overload by cardiac and liver T2* in \u03b2-thalassemia: correlation with serum ferritin, heart function and liver enzymes. J Cardiovasc Thorac Res. 2021, 13:54-60. 10.34172\/jcvtr.2021.18","journal-title":"J Cardiovasc Thorac Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-00997-7","article-title":"Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat","volume":"19","author":"Park SH","year":"2020","unstructured":"Park SH, Farooq MA, Gaertner S, et al.. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovasc Diabetol. 2020, 19:19. 10.1186\/s12933-020-00997-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2023.107212","article-title":"Empagliflozin decreases ageing-associated arterial stiffening and vascular fibrosis under normoglycemic conditions","volume":"152","author":"Neutel CHG","year":"2023","unstructured":"Neutel CHG, Wesley CD, Van Praet M, et al.. Empagliflozin decreases ageing-associated arterial stiffening and vascular fibrosis under normoglycemic conditions. Vascul Pharmacol. 2023, 152:107212-10. 10.1016\/j.vph.2023.107212","journal-title":"Vascul Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/289550-impact-of-empagliflozin-on-the-outcomes-of--thalassemia-major-in-patients-with-type-2-diabetes-mellitus-the-thalempa-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T09:40:00Z","timestamp":1726911600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/289550-impact-of-empagliflozin-on-the-outcomes-of--thalassemia-major-in-patients-with-type-2-diabetes-mellitus-the-thalempa-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.69837","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,21]]}}}